Depending on tumor type, KLF4 is thought to be a tumor suppressor in gastrointestinal, esophageal, lung, and pancreatic cancers (Evans & Liu, 2008; Hung et al, 2013; Wei et al, 2016), while it acts as an oncogenic player in breast and squamous cell carcinoma (Foster et al, 1999; Foster et al, 2000; Pandya et al, 2004; Foster et al, 2005; Rowland et al, 2005; Dong et al, 2014). Here, KLF4 is linked to familial pancreatic carcinoma.